Trial Profile
A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs IRL 201104 (Primary) ; IRL 201104 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Immune Regulation; Peptinnovate; Revolo Biotherapeutics
- 26 Nov 2018 Results presented in an Immune Regulation Media Release.
- 22 Nov 2018 According to an Immune Regulation media release, Peptinnovate acquired Immune Regulation Ltd. earlier this year and today the company announced that that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect.
- 23 Jan 2018 Status changed from recruiting to completed.